Acumen Pharmaceuticals (ABOS)
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on ad...
- Open
- 3.070
- High
- 3.230
- Low
- 3.030
- Prev. Close
- 3.090
- Volume
- 315.43K
- Turnover
- 996.68K
- Avg Price
- 3.160
- Bid/Ask Ratio
- 0.00%
- Amplitude
- 6.47%
- 52wk High
- 3.600
- Volume Ratio
- 1.41
- Turnover Ratio
- 0.85%
Acumen Pharmaceuticals Analyst Rating
View moreForecast & Rating
Aug 14, 2026Price forecast
$7.40132.70%
Forecast & RatingStrong buy
6analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Sep 5 at 07:24 AM
BlackRock Inc. Makes New Investment in Acumen Pharmaceuticals, Inc. $ABOS
- Unusual Whales · Sep 2 at 08:01 PM
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
- PUBT · Sep 2 at 08:00 PM
Acumen Pharmaceuticals to present at Cantor Global Healthcare Conference fireside chat
- Tip Ranks · Aug 24 at 12:28 AM
Acumen Pharmaceuticals Earnings Call: Science vs. Runway
- TradingKey · Aug 14 at 08:04 AM
Acumen Pharmaceuticals (ABOS) Q2 2026 Earnings Call: ALTITUDE-AD Readout Due Late 2026
